Spermatogenic Failure 88 (SPGF88): A Comprehensive Disease Characterization Report

Causal gene: KASH5 (also known as CCDC155; aliases POF22, HYDM6), chromosome 19q13.33, NCBI Gene 147872, Ensembl ENSG00000161609, UniProt Q8N6L0.

Identifier verification. The research template supplied MONDO:0957821. This term maps to OMIM 620547, MedGen C5882706, and the NCBI gene link for this concept points unambiguously to KASH5 / CCDC155 (Gene ID 147872) at 19q13.33. This report therefore describes the KASH5-related disease, not any similarly numbered SPGF entry caused by a different gene.

Summary

Spermatogenic failure 88 (SPGF88; MONDO:0957821; OMIM 620547) is an ultra-rare, autosomal recessive form of male infertility caused by biallelic loss-of-function variants in KASH5, also known as CCDC155 (NCBI Gene 147872; aliases KASH5, POF22, HYDM6), located on chromosome 19q13.33. KASH5 encodes the meiosis-specific outer-nuclear-membrane dynein adaptor of the SUN1–KASH5 LINC complex (Linker of Nucleoskeleton and Cytoskeleton). This complex physically couples meiotic telomeres, through the nuclear envelope, to cytoplasmic dynein and the microtubule cytoskeleton, generating the telomere-led chromosome movements that drive homologous-chromosome pairing and synapsis during meiotic prophase I.

When KASH5 function is lost, telomere-led chromosome movements and "bouquet" formation fail, homologous chromosomes do not pair or synapse, and meiotic DNA double-strand breaks (DSBs) are left unresolved. The consequence is an arrest of spermatogenesis at the zygotene-like (pre-pachytene) stage, which manifests clinically as non-obstructive azoospermia (NOA) — the complete absence of spermatozoa in the ejaculate due to a spermatogenic (rather than obstructive) defect. The identical molecular lesion causes premature ovarian insufficiency (POI/POF22) in females, making this a shared male–female meiotic-arrest disorder. Kash5-knockout mice faithfully recapitulate the human zygotene arrest and are infertile in both sexes, providing strong cross-species mechanistic confirmation.

Three independent human reports (Fakhro et al. 2018; Wu et al. 2022; Yang et al. 2022) establish KASH5/CCDC155 as a bona fide human NOA gene, with pathogenic alleles spanning frameshift, whole/partial-gene-deletion CNV, splice-site, and coiled-coil missense classes — all converging on loss of LINC-complex function. There is no curative therapy; management centers on genetic counseling and assisted reproduction (with donor sperm the likely route given expected poor surgical sperm-retrieval yield). This report compiles disease information, etiology, phenotypes, genetics, mechanism, affected anatomy, temporal course, epidemiology, diagnostics, prognosis, treatment, prevention, and comparative/model-organism biology across all 15 requested sections.

Key Findings

Finding 1 — SPGF88 is caused by biallelic KASH5/CCDC155 loss-of-function variants at 19q13.33

OMIM 620547 and MedGen C5882706 map SPGF88 to the gene KASH5 (NCBI Gene 147872; aliases CCDC155, POF22, HYDM6) at 19q13.33. In the index genotype, Yang et al. 2022 identified a heterozygous copy-number deletion del(19)(q13.33) (chr19:g.49894043-49903011del) in trans with a heterozygous frameshift LoF variant NM_144688:c.979_980del, p.(Arg327Serfs*21) in a man with non-obstructive azoospermia and in his infertile sister. This compound-heterozygous (biallelic) configuration abolishes functional KASH5 and produced spermatogenic arrest at a zygotene-like stage.

"a novel heterozygous copy number variation (CNV) (seq [GRCh37] del(19) (19q13.33) chr19: g.49894043-49903011del) and a heterozygous loss of function variant (NM_144688: c.979_980del: p.R327Sfs21) in human KASH5 were identified in a non-obstructive azoospermia (NOA)-affected patient and in his infertile sister"* — PMID: 35674372

This is the anchoring genetic finding: it establishes the gene, the locus, the biallelic recessive mechanism, and the loss-of-function variant classes (frameshift + CNV deletion).

Finding 2 — KASH5 loss arrests meiosis at the zygotene stage via failed homolog pairing/synapsis (conserved human–mouse mechanism)

In the human KASH5-deficient proband, spermatogenesis arrested at a zygotene-like stage with deficient homolog pairing and synapsis. This directly mirrors the original Kash5-null mouse (Horn et al. 2013), in which males show meiotic arrest with failed pairing of homologous chromosomes and resulting infertility in both sexes. The concordance across species confirms the human phenotype is a direct consequence of lost LINC-complex–mediated telomere–cytoskeleton coupling.

"Males display meiotic arrest in which pairing of homologous chromosomes fails. These findings demonstrate that telomere attachment to the NE is insufficient to promote pairing and that telomere attachment sites must be coupled to cytoplasmic dynein and the microtubule system to ensure meiotic progression." — PMID: 24062341

"Spermatogenesis in the proband was arrested at zygotene-like stage with a deficiency in homolog pairing and synapsis" — PMID: 35674372

Finding 3 — KASH5 is loss-of-function–tolerant in gnomAD, consistent with a recessive mechanism

gnomAD v4 constraint metrics for KASH5 (ENSG00000161609) show the gene is not depleted of heterozygous LoF variants: pLI ≈ 0 (2.96×10⁻²¹), observed/expected LoF = 0.85 (90% CI 0.71–1.04; LOEUF ≈ 1.04), with 72 observed vs 84 expected LoF variants. This tolerance of heterozygous LoF is exactly what is expected for an autosomal recessive disease gene — heterozygous carriers are unaffected and disease requires biallelic hits. It also argues against a dominant-negative or haploinsufficiency model.

Finding 4 — A homozygous coiled-coil missense (p.Leu197Pro) causes NOA and POI by mislocalizing the LINC complex

Wu et al. 2022 performed whole-exome sequencing on 15 consanguineous NOA/POI patients and identified a homozygous missense variant in the conserved coiled-coil (CC) domain of CCDC155/KASH5, c.590T>C, p.(Leu197Pro), in a brother–sister pair whose parents were first cousins. Functionally, the variant blocked nuclear-envelope (NE) distribution of KASH5 and prevented NE-specific enrichment of SUN1, and affected spermatocytes failed to complete meiotic division with unresolved DNA double-strand-break repair. This adds a missense variant class and an explicit DSB-repair-failure step to the mechanism. Per UniProt Q8N6L0, KASH5 is a 562-aa protein with a coiled-coil domain (residues 164–349) and a C-terminal transmembrane KASH anchor (522–542); it localizes to telomeres from leptotene to diplotene.

"identified a novel homozygous missense mutation in CCDC155 [c.590T>C (p.Leu197Pro)] in a pair of familial NOA and POI patients whose parents were first cousins" — PMID: 35587281

"blocked nuclear envelope (NE) distribution and subsequently prevented NE-specific enrichment of Sad1- and UNC84-domain-containing 1 either ex vivo or in vitro" — PMID: 35587281

Finding 5 — First human KASH5–NOA link (Fakhro et al. 2018) and the authoritative HPO annotation set

Fakhro et al. 2018 (Genetics in Medicine) performed WES across 8 consanguineous Middle Eastern (Qatari) NOA families and identified rare deleterious recessive variants in CCDC155 (KASH5) — along with NANOS2, SPO11, TEX14, and WNK3 — segregating with disease, the earliest human evidence for KASH5-related NOA and a foundational source for OMIM 620547. The official Human Phenotype Ontology annotations for OMIM:620547 (ontology.jax.org) are: HP:0003251 Male infertility (3/3 patients), HP:0011961 Non-obstructive azoospermia (3/3), HP:0031039 Spermatocyte maturation arrest (2/2), HP:0011462 Young adult onset (2/2), and HP:0000007 Autosomal recessive inheritance.

"we identified rare deleterious recessive variants in CCDC155, NANOS2, SPO11, TEX14, and WNK3 segregating with disease. These genes, which are novel to human NOA, have remarkable testis-specific expression" — PMID: 29790874

"Nonobstructive azoospermia (NOA) affects 1% of the male population" — PMID: 29790874

Section-by-Section Report

1. Disease Information

SPGF88 is a monogenic (Mendelian), autosomal recessive form of non-obstructive azoospermia — a spermatogenic failure in which no spermatozoa reach the ejaculate because germ-cell development is arrested within the testis, with patent excurrent ducts. It is one of a numbered series of "spermatogenic failure" OMIM entries, each defined by its causal gene; SPGF88's gene is KASH5/CCDC155.

Key identifiers: - OMIM: 620547 - MONDO: MONDO:0957821 - MedGen: C5882706 - Gene: KASH5 / CCDC155 (NCBI Gene 147872; Ensembl ENSG00000161609; UniProt Q8N6L0) - Locus: 19q13.33 - ICD-10: N46.x (male infertility; no SPGF88-specific code); ICD-11: GB04 (male infertility). No disease-specific ICD code exists. - Orphanet / MeSH: No SPGF88-specific entry; subsumed under azoospermia / male infertility (MeSH D053713 Azoospermia).

Synonyms / alternative names: Spermatogenic failure 88; SPGF88; non-obstructive azoospermia due to KASH5/CCDC155 deficiency. The female-manifesting counterpart at the same locus is designated POF22 (premature ovarian failure 22).

Source of information: Aggregated, disease-level resources (OMIM, MedGen, HPO) built from a small number of individual-patient case reports in consanguineous/familial cohorts — not from large EHR datasets. The total reported human caseload is a handful of patients across three publications.

2. Etiology

Primary cause — genetic. SPGF88 is caused exclusively by biallelic (homozygous or compound-heterozygous) loss-of-function variants in KASH5/CCDC155. No environmental, infectious, or acquired cause is implicated; this is a pure Mendelian meiotic defect.

Genetic risk factors. The causal variants reported span several classes, all converging on loss of KASH5 function: - Frameshift LoF: c.979_980del, p.(Arg327Serfs*21) (Yang 2022) - Whole/partial-gene deletion CNV: del(19)(q13.33) chr19:g.49894043-49903011del (Yang 2022) - Coiled-coil missense: c.590T>C, p.(Leu197Pro) (Wu 2022) - Splice-site (in the POI-manifesting form): c.747G>A (Zhang et al. 2022, POI pedigree) - Rare deleterious recessive variant(s) in CCDC155 (Fakhro 2018)

Consanguinity is the dominant risk modifier: homozygous cases arose in first-cousin unions (Wu 2022; Fakhro 2018), reflecting the general pattern for ultra-rare recessive disease.

Environmental / lifestyle / infectious risk factors: None known or expected for this monogenic disorder. General NOA risk factors (heat, toxins, chemotherapy, Y-microdeletions, Klinefelter syndrome) are differential diagnoses, not contributors to SPGF88 itself.

Protective factors: None identified. By inference, a single functional KASH5 allele is fully protective (carriers are fertile and unaffected), consistent with the gnomAD LoF tolerance (Finding 3).

Gene–environment interactions: None documented; the phenotype is fully penetrant genetically without a known environmental trigger.

3. Phenotypes

The phenotype is reproductive and, in males, essentially monosymptomatic at the organismal level.

Characteristics. Onset is effectively congenital at the cellular level (the meiotic machinery is defective from the first wave of spermatogenesis) but is clinically recognized in young adulthood when infertility prompts evaluation. Severity is severe (complete azoospermia; no spontaneous conception possible), the course is stable/non-progressive in males (no systemic decline), and penetrance for infertility appears complete in biallelic individuals.

Quality-of-life impact. The burden is confined to reproduction: inability to father children biologically, with the attendant psychological and relationship impact well documented for NOA generally. There is no systemic morbidity, pain, or reduction in life expectancy. No disease-specific QoL instrument data (EQ-5D/SF-36) exist for SPGF88; impact is inferred from the broader NOA/infertility literature.

4. Genetic/Molecular Information

Causal gene: KASH5 / CCDC155 (NCBI Gene 147872; Ensembl ENSG00000161609; UniProt Q8N6L0), 19q13.33. Transcript reference NM_144688. The protein is 562 aa with a central coiled-coil domain (aa 164–349) and a C-terminal KASH transmembrane anchor (aa 522–542).

Pathogenic variants (all germline):

Allele frequency: All reported variants are rare/private; KASH5 is not depleted of LoF in gnomAD (Finding 3), consistent with rare recessive carriers in the general population.

Functional consequence: Loss of function across all variant classes — truncation/deletion removes the protein; the p.Leu197Pro missense abolishes NE localization and SUN1 recruitment. No gain-of-function or dominant-negative mechanism is supported (the gene's LoF tolerance argues against dominant effects).

Modifier genes: None established. Functional partners whose loss produces overlapping meiotic-arrest phenotypes include SUN1, SPDYA (Speedy A)/CDK2, and the telomere-attachment machinery (TERB1/TERB2/MAJIN), but these are separate SPGF/POI loci, not SPGF88 modifiers.

Epigenetic information: None specific to SPGF88 reported.

Chromosomal abnormalities: The CNV deletion at 19q13.33 removing KASH5 (Yang 2022) is the relevant large-scale lesion; otherwise the karyotype is normal (SPGF88 is distinct from Klinefelter/Y-microdeletion azoospermia).

5. Environmental Information

Not applicable. SPGF88 is a monogenic meiotic disorder with no established environmental, lifestyle (smoking/diet/alcohol/exercise), or infectious contribution. Such factors belong to the differential diagnosis of acquired/idiopathic NOA, not to this entity.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. Biallelic LoF variant in KASH5/CCDC155 (frameshift, CNV deletion, splice, or coiled-coil missense) leads to absence or mislocalization of functional KASH5 protein.
2. Loss of KASH5 at the outer nuclear membrane results in failure to assemble the meiosis-specific SUN1–KASH5 LINC complex at telomere attachment sites (demonstrated: p.Leu197Pro blocks NE distribution and SUN1 enrichment).
3. Absent LINC complex leads to failure to recruit cytoplasmic dynein and couple telomeres to the microtubule cytoskeleton (KASH5 is the dynein adaptor).
4. Loss of dynein/microtubule coupling results in loss of telomere-led rapid chromosome movements and failure of meiotic "bouquet" formation (inferred in human from mouse; demonstrated in mouse).
5. Absent chromosome movements lead to failed homologous-chromosome pairing and synapsis (demonstrated in human proband and in Kash5-null mice).
6. Failed synapsis results in unresolved meiotic DNA double-strand-break (DSB) repair (demonstrated for p.Leu197Pro spermatocytes).
7. Unresolved DSBs and asynapsis trigger the meiotic checkpoint and arrest at the zygotene-like (pre-pachytene) stage (demonstrated).
8. Meiotic arrest leads to germ-cell elimination / spermatocyte maturation arrest, so no haploid spermatids or spermatozoa form.
9. Absence of spermatozoa manifests as non-obstructive azoospermia and male infertility (clinical endpoint).
10. Branch (female): The identical LINC-complex failure in oocytes leads to accelerated oocyte depletion and premature ovarian insufficiency (POF22).

Upstream vs downstream: Steps 1–3 (variant → LINC assembly failure → dynein uncoupling) are upstream molecular causes; steps 5–7 (asynapsis, DSB persistence, checkpoint arrest) are the midstream meiotic failures; steps 8–9 (germ-cell loss, azoospermia) are the downstream clinical outcomes.

Molecular pathways / processes: Meiotic telomere clustering and bouquet formation; LINC-complex nucleocytoskeletal coupling; dynein/microtubule-based chromosome motility; meiotic homologous recombination / DSB repair; synaptonemal-complex assembly. KASH5 also participates in the SUN1–SPDYA–CDK2 telomere architecture (PMID: 34039995).

Protein dysfunction: Loss of the KASH anchor (truncation/deletion) or loss of coiled-coil–mediated NE targeting (p.Leu197Pro) prevents KASH5 from bridging the perinuclear space and binding SUN1 — a loss-of-function structural defect. No experimental structure of human KASH5 has been deposited in the PDB (verified); the AlphaFold model of Q8N6L0 is the available structural proxy.

Suggested GO / CL terms: - GO:0007129 homologous chromosome pairing at meiosis - GO:0007130 synaptonemal complex assembly - GO:0070197 meiotic attachment of telomere to nuclear envelope - GO:0034993 meiotic nuclear membrane microtubule tethering complex - GO:0051321 meiotic cell cycle - GO:0000724 DSB repair via homologous recombination - Cellular component: GO:0005640 nuclear outer membrane; GO:0034993 LINC complex - CL:0000017 / CL:0000656 spermatocyte; CL:0000020 spermatogonium; CL:0000023 oocyte

7. Anatomical Structures Affected

• Organ level (primary): Testis (UBERON:0000473); specifically the seminiferous tubules (UBERON:0001343). Female counterpart: ovary (UBERON:0000992).
• Body system: Male reproductive system (UBERON:0000079); the endocrine axis is typically intact (a hypergonadotropic pattern is possible secondary to germ-cell loss).
• Tissue/cell level: Germinal epithelium; the targeted population is the primary spermatocyte (CL:0000656 / CL:0000017) arrested at zygotene. Somatic Sertoli and Leydig cells are not the primary defect. In females, oocytes (CL:0000023).
• Subcellular level: Nuclear envelope / outer nuclear membrane (GO:0005640); telomere attachment sites; the LINC complex spanning the perinuclear space; nucleus–cytoskeleton interface.
• Localization / lateralization: Bilateral (both testes affected), symmetric. Testicular volume may be preserved or reduced; ducts are patent (non-obstructive).

8. Temporal Development

• Onset: Cellular defect is congenital (present from the first meiotic wave at puberty); clinical onset is young-adult (HP:0011462), when infertility is discovered. Onset pattern is insidious/chronic — there is no acute event.
• Progression: Stable and non-progressive in males — azoospermia is a fixed developmental block, not a degenerative process; lifelong/chronic. In females, the ovarian phenotype (POF22) is progressive (accelerated depletion of the oocyte pool).
• Patterns: No remission; no relapsing course. The critical period is meiotic prophase I — the window in which the LINC complex is required — which is irreversibly missed.

9. Inheritance and Population

• Inheritance: Autosomal recessive (HP:0000007); biallelic variants required. Heterozygous carriers are unaffected (consistent with gnomAD LoF tolerance, Finding 3).
• Penetrance: Appears complete for infertility in biallelic males within reported families (small n).
• Expressivity: Consistent severe phenotype (azoospermia) in males; sex-specific expressivity (NOA in males, POI in females) at the same locus.
• Consanguinity: Major contributor — homozygous cases arose in first-cousin families (Wu 2022; Fakhro 2018, Qatari cohort).
• Founder effects / carrier frequency: None established; variants are private/rare. KASH5 is not LoF-depleted in gnomAD, so rare carriers exist broadly.
• Epidemiology: No SPGF88-specific prevalence/incidence exists — it is an ultra-rare monogenic cause within the broad NOA category. Context: "Nonobstructive azoospermia (NOA) affects 1% of the male population" (PMID: 29790874). In the Fakhro consanguineous-cohort analysis, a genetic etiology was found in 13.3% of idiopathic NOA families vs 0 controls (p=0.001), of which CCDC155 was one contributing gene.
• Demographics: Reported in Middle Eastern (Qatari) and East Asian (Chinese) consanguineous/familial settings; this reflects ascertainment in consanguineous populations rather than true geographic restriction. Sex ratio is not meaningful (the male disorder affects males; the allelic female disorder is POF22).

10. Diagnostics

• Semen analysis: Confirms azoospermia (no sperm on centrifuged pellet) across ≥2 samples — the defining laboratory test.
• Hormonal profile: FSH/LH/testosterone to classify as non-obstructive (often elevated FSH with germ-cell loss); distinguishes from obstructive azoospermia.
• Physical/imaging: Scrotal ultrasound to exclude obstruction; testicular volume assessment.
• Testicular histopathology/biopsy: Spermatocyte maturation (meiotic) arrest at zygotene/pre-pachytene (HP:0031039) — the pathognomonic histology.
• Genetic testing — the definitive diagnostic: First exclude Y-chromosome microdeletions and karyotype (Klinefelter). Then whole-exome sequencing (WES) or a male-infertility/NOA gene panel including CCDC155/KASH5 identifies biallelic variants. Chromosomal microarray / CNV analysis is needed to detect the 19q13.33 deletion allele (as in Yang 2022, where one allele was a CNV). Single-gene testing of KASH5 is appropriate where a familial variant is known.
• Omics: KASH5/CCDC155 shows testis-specific expression (PMID: 29790874), supporting candidacy; research scRNA-seq frameworks are emerging for NOA gene prioritization but are not clinical.
• Differential diagnosis: Obstructive azoospermia (normal FSH, patent-duct defect), Klinefelter (47,XXY), Y-microdeletions (AZFa/b/c), and other monogenic meiotic-arrest genes (SYCP3, TEX11, MEIOB, SPO11, STAG3, SUN1, etc.). SPGF88 is distinguished by biallelic KASH5 variants + zygotene arrest.
• Screening: Carrier screening/cascade testing of relatives is relevant in consanguineous families once the familial variant is known.

11. Outcome / Prognosis

• Survival/mortality: No effect on life expectancy or mortality — SPGF88 is confined to fertility. Not applicable for survival metrics.
• Morbidity: The sole morbidity is infertility and its psychosocial impact.
• Disease course/complications: Stable; no organ failure or systemic complications. The female allelic disorder (POF22) adds the morbidity of early estrogen deficiency and its sequelae.
• Recovery potential: The meiotic block is developmentally fixed and not reversible by medical therapy. Surgical sperm retrieval (micro-TESE) yield is expected to be poor because the arrest is complete and early (pre-pachytene); no mature or post-meiotic cells are produced.
• Prognostic factors: The nature of the variant (complete LoF vs hypomorphic) may in principle influence residual spermatogenesis, but all reported cases showed azoospermia; no favorable prognostic biomarker is established.

12. Treatment

• Curative therapy: None exists. No pharmacotherapy restores LINC-complex function or reverses meiotic arrest.
• Assisted reproduction: Because sperm retrieval is expected to fail, the realistic path to biological parenthood for the couple is donor-sperm insemination/IVF or adoption. Micro-TESE with ICSI may be attempted but counseled as low-yield given early complete arrest. (NCIT:C15215 Assisted Reproductive Technology; NCIT:C92948 Genetic Counseling.)
• Gene/cell/RNA therapy, targeted/immunotherapy: Not applicable / none in trials for this indication.
• Supportive care: Reproductive counseling and psychological support.
• Personalized medicine: Genetic diagnosis chiefly informs prognosis (predicting poor TESE yield) and family planning rather than drug selection.

13. Prevention

• Primary prevention: Not applicable (genetic disorder; no modifiable exposure).
• Genetic counseling (central): For consanguineous couples or families with a known KASH5 variant — counseling on the 25% recurrence risk per pregnancy in carrier×carrier unions, and on the male/female (NOA/POI) implications of the shared locus.
• Reproductive options: Carrier screening, cascade testing of relatives, preimplantation genetic testing (PGT-M) or prenatal testing when the familial variant is known, and donor gametes.
• Public-health / behavioral / immunization measures: Not applicable.

14. Other Species / Natural Disease

• Taxonomy / orthologs: Mouse Kash5 (also Ccdc155) is the principal ortholog (conserved LINC-complex function). The gene and mechanism are evolutionarily conserved across mammals; related telomere-attachment LINC machinery is documented even on vole B chromosomes (PMID: 42479255).
• Natural disease in animals: No spontaneous companion-animal/wildlife KASH5 disease is catalogued in OMIA; relevance is experimental rather than veterinary.
• Comparative biology: The Kash5-null mouse reproduces the human phenotype closely (zygotene meiotic arrest, failed pairing, bilateral infertility), indicating deep conservation of the meiotic-telomere-coupling mechanism.
• Transmission: Not applicable (non-communicable genetic disorder).

15. Model Organisms

• Mouse (Mus musculus): The Kash5-knockout and Kash5 C-terminal-deleted mice are the key models.
• Horn et al. 2013 (PMID: 24062341): KO males show meiotic arrest with failed homolog pairing; both sexes infertile — establishing the mechanism.
• Zhang et al. 2022 (PMID: 35708642): Kash5 C-terminal-deleted mice show defective homolog pairing and accelerated oocyte depletion, modeling the female (POI/POF22) phenotype.
• In vitro / ex vivo systems: Wu et al. 2022 used ex vivo and in vitro assays to show the p.Leu197Pro missense blocks KASH5 NE distribution and SUN1 enrichment — a cell-based functional model of the human missense allele.
• Structural models: The SUN1–SPDYA–CDK2 crystal structure (PMID: 34039995) and EM tomography of mouse LINC complexes at telomere attachment sites (PMID: 31633067; ~76 LINC complexes estimated per telomere attachment site) illuminate the molecular architecture KASH5 participates in.
• Phenotype recapitulation: High — the mouse reproduces the defining human feature (zygotene arrest, pairing/synapsis failure, azoospermia/infertility), making it a faithful model. Limitation: mouse models and cell assays cannot fully capture human testicular histologic variability or the potential for rare residual spermatogenesis.
• Resources: MGI (mouse Kash5/Ccdc155); IMPC/IMSR for alleles.

Mechanistic Model (Synthesis)

 Biallelic KASH5/CCDC155 LoF variant (19q13.33)
   [frameshift p.R327Sfs*21 | CNV del(19)(q13.33) | CC missense p.L197P | splice c.747G>A]
            │  loss of / mislocalized KASH5 protein
            ▼
 Failure to assemble SUN1–KASH5 LINC complex at the nuclear envelope
            │  (p.L197P blocks NE distribution + SUN1 enrichment — demonstrated)
            ▼
 KASH5 cannot recruit cytoplasmic dynein → telomeres uncoupled from microtubules
            ▼
 Loss of telomere-led chromosome movement & bouquet formation (mouse-demonstrated)
            ▼
 Failed homologous pairing & synapsis  ──►  Unresolved meiotic DSB repair
            │                                         │
            └───────────────┬─────────────────────────┘
                            ▼
          Meiotic checkpoint arrest at ZYGOTENE-like (pre-pachytene) stage
                            ▼
          Germ-cell elimination / spermatocyte maturation arrest
                            ▼
        ┌─────────────────────────────┬───────────────────────────────┐
        ▼ (male)                       ▼ (female, same locus)
 Non-obstructive azoospermia      Accelerated oocyte depletion →
 → male infertility (SPGF88)      Premature ovarian insufficiency (POF22)

The model is strongly supported: every step from LINC-complex assembly failure through zygotene arrest is demonstrated in either human patients (NE-targeting/SUN1 recruitment, zygotene arrest, DSB persistence) or the mouse (pairing failure, bouquet dependence), with cross-species concordance. The only inferred (vs directly demonstrated-in-human) step is the loss of telomere-led movement/bouquet formation, which rests on mouse and cell-biological evidence.

Evidence Base

All PMIDs above appear in the reviewed literature and directly support the cited claims. Papers in the literature list concerning unrelated NOA genetics (Y-microdeletions, DMRT1, POLG, miRNAs, Fas/FasL, cancer-variant load) were reviewed for context on the broader NOA landscape but do not bear on the KASH5 mechanism and are not cited as evidence for SPGF88-specific claims.

Limitations and Knowledge Gaps

1. Very small human sample size. The entire human evidence base for SPGF88 rests on a handful of patients across three families/cohorts. Penetrance, expressivity, and genotype–phenotype correlations cannot be robustly estimated.
2. No epidemiology. There is no prevalence/incidence estimate specific to SPGF88; it is an ultra-rare monogenic slice of the ~1% NOA population.
3. CNV detectability. One pathogenic allele was a 19q13.33 deletion, meaning WES/panel sequencing alone can miss the second allele; CNV/array analysis is required but not always performed.
4. No human protein structure. No experimental KASH5 structure is deposited in the PDB; structural interpretation of missense variants (e.g., p.Leu197Pro) relies on domain annotation and AlphaFold.
5. Residual spermatogenesis unknown. Whether any hypomorphic allele permits rare post-meiotic cells (and thus TESE success) has not been demonstrated; all reported cases are azoospermic.
6. Inferred steps. Loss of telomere-led movement/bouquet in human patients is inferred from mouse/cell data rather than directly imaged in patient spermatocytes.
7. No therapeutics. There is no disease-modifying treatment and no clinical trial; management is supportive/reproductive.

Proposed Follow-up Experiments / Actions

1. Expand the patient series via international consortia (e.g., GeneMatcher, IMIGC) to collect additional biallelic KASH5 cases, enabling genotype–phenotype and penetrance estimates.
2. Always pair WES with CNV/array analysis in NOA diagnostics for KASH5, given the demonstrated compound-het CNV allele; report variants to ClinVar to build classification evidence.
3. Patient testicular histology + immunostaining (SYCP1/SYCP3 synapsis markers, γH2AX for DSBs, telomere/LINC markers) to directly confirm the inferred bouquet/movement defect in humans.
4. Functional assays for each new variant (NE-localization and SUN1/dynein-binding assays as in Wu 2022) to classify VUS and distinguish complete-LoF from hypomorphic alleles.
5. Correlate variant severity with micro-TESE outcome prospectively to establish whether any allele predicts rare sperm retrieval, refining counseling.
6. Structural determination (cryo-EM/crystallography) of the human KASH5 coiled-coil and KASH–SUN1 interface to mechanistically interpret missense variants.
7. iPSC-derived germ-cell or organoid models carrying patient variants to study the human meiotic block and screen for rescue strategies.
8. Carrier/cascade screening and PGT-M counseling in affected consanguineous families as a concrete clinical action.

Report compiled from 5 iterations, 5 confirmed findings, and 19 reviewed papers. Evidence spans human clinical case reports, mouse knockout models, in vitro functional assays, and structural/computational data, as indicated per claim.